A large study reveals an increased risk for adverse cardiovascular events but not for liver disease progression in adults with MASLD disease and HIV infection.
GLP-1 agonists could be a treatment option to reduce the risk for major adverse liver outcomes in adults with type 2 diabetes and chronic liver disease.
The overall cancer risk was higher in individuals with T2D at a younger age, and the risk decreased as age increased at diagnosis, a prospective study in China found.